Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Almost half of women with the most common form of early breast cancer could be spared chemotherapy thanks to a genetic test, research suggests.
The Oncotype DX test involves the examination of genes taken from a sample of a tumour removed during surgery.
It can help doctors decide whether chemotherapy would actually benefit patients and the risk of cancer returning.
Research carried out by Simon Holt, a breast surgeon at the Hywel Dda Health Board in Wales, found that 46% of patients with early stage disease could be spared unnecessary chemotherapy.
The 142 NHS patients in his study had oestrogen receptor positive breast cancer, the most common type, and had initially been offered chemotherapy and hormone therapy.
The Oncotype DX test is currently being reviewed by the National Institute for Health and Clinical Excellence (Nice) for widespread use on the NHS.
Mr Holt said: "With nearly 50,000 women diagnosed with early stage breast cancer each year in the UK, a genomic test like Oncotype DX that is capable of predicting treatment benefits and/or outcomes may have an important role to play in improving treatment decision making and ultimately impacting on quality of care.
"Oncotype DX allows us to use our health funds more effectively while sparing patients from unnecessary chemotherapy."
Mr Holt presented his findings at the San Antonio Breast Cancer Symposium last week.
PA
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments